BioCentury
ARTICLE | Financial News

AAV plasmid company StrideBio raises $15.7M series A

June 15, 2018 7:28 PM UTC

StrideBio Inc. (Durham, N.C.) raised $15.7 million in a series A round led by existing investor Hatteras Venture Partners with participation from new investors Takeda Ventures, UCB Ventures and Alexandria Venture Investments. StrideBio COO Richard Smith told BioCentury the round gives the adeno-associated viral vector plasmid company a cash runway into 2019.

StrideBio is developing preclinical AAV capsids. According to Smith, the capsids are designed to avoid neutralizing antibodies in the liver, muscle, eye and CNS tissues while retaining tropism, transduction efficiency and capacity for manufacture. The company plans to focus on treating rare diseases...